JPMORGAN CHASE & CO - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 33 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2017. The put-call ratio across all filers is 0.75 and the average weighting 0.0%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2023$8
-61.9%
39
+290.0%
0.00%
Q2 2023$21
-99.8%
10
-99.7%
0.00%
Q1 2023$10,000
-98.1%
2,983
-98.4%
0.00%
Q2 2022$516,000
-37.6%
187,070
-24.0%
0.00%
Q1 2022$827,000
+7.0%
246,202
+27.5%
0.00%
Q4 2021$773,000
-47.5%
193,166
-56.7%
0.00%
Q3 2021$1,471,000
-44.6%
445,698
-36.2%
0.00%
Q2 2021$2,653,000
-14.0%
698,294
-13.3%
0.00%
Q1 2021$3,085,000
+73.7%
805,438
+105.3%
0.00%
Q4 2020$1,776,000
+932.6%
392,417
+3585.7%
0.00%
Q3 2020$172,000
+70.3%
10,647
+18.7%
0.00%
Q2 2020$101,000
-70.2%
8,970
-87.7%
0.00%
Q1 2020$339,000
+3666.7%
72,977
+3523.5%
0.00%
Q4 2019$9,000
-97.7%
2,014
-98.1%
0.00%
Q3 2018$395,000
-22.1%
103,506
-20.4%
0.00%
Q2 2018$507,000
+645.6%
130,086
+683.9%
0.00%
Q3 2017$68,00016,5940.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q3 2017
NameSharesValueWeighting ↓
ABNER HERRMAN & BROCK LLC 241,500$1,093,0000.17%
OCCUDO QUANTITATIVE STRATEGIES LP 90,584$410,0000.13%
EPIQ PARTNERS, LLC 10,550$48,0000.03%
Phoenix Holdings Ltd. 173,683$799,0000.02%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 5,500$25,0000.02%
CFO4Life Group, LLC 12,003$54,0000.02%
HighPoint Advisor Group LLC 15,733$115,0000.01%
VOLORIDGE INVESTMENT MANAGEMENT, LLC 357,761$1,619,0000.01%
Virtu Financial LLC 24,484$111,0000.01%
ETF MANAGERS GROUP, LLC 93,902$435,0000.01%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders